Selecta Biosciences (SELB) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $140.0M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Selecta Biosciences (SELB) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $140.0M

Selecta Biosciences (SELB) Announces Top Line Data from Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR in Gene Therapy

November 8, 2021 8:13 AM EST

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies. At day 30, in those subjects administered a single 0.3 mg/kg dose of ImmTOR, Selecta observed a median anti-AAV8 neutralizing antibody titer of 1:5, a 250-fold lower level... More